BriaCell Therapeutics Corp. (BCTXZ)
NCM
Closing price as of 2026-08-12 · Source: TEK2day Finance
Key Metrics
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Quarterly Financials
| Metric | 2025-04-30 | 2025-10-31 | 2026-01-31 | 2026-04-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (6.3M) | (8.3M) | (7.5M) | (7.6M) |
| Net Income | (6.1M) | (8.2M) | (7.2M) | (7.2M) |
Annual Financials
| Metric | 2021-07-31 | 2022-07-31 | 2023-07-31 | 2024-07-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (7.0M) | (15.3M) | (23.3M) | (33.3M) |
| Net Income | (13.8M) | (26.8M) | (20.3M) | (4.8M) |